At the intersection of endomyocardial biopsy and dd-cfDNA, where do we go?
Blood tests may soon replace painful heart biopsies for monitoring transplant rejection, potentially transforming how doctors protect donated hearts.
This perspective explores how donor-derived cfDNA is changing the landscape of cardiac transplant rejection monitoring, traditionally reliant on invasive endomyocardial biopsy. The article considers integration pathways and remaining evidence gaps for cfDNA adoption.
What the study was
- Study design
- Perspective/Commentary
- Population
- Cardiac transplant recipients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Cardiovascular Pathology
Why it surfaced
Relevant cfDNA perspective but not cancer-focused. Included for liquid biopsy topic coverage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.